Prace polskich autorów przedstawione podczas kongresu ASCO 2018

5 czerwca 2018

Prace polskich autorów przedstawione podczas kongresu ASCO odbywającego się w dniach 1-5 czerwca 2018 w Chicago:

  1. Kieszkowska-Grudny A. i wsp. 10121 - "Intensive 4-weeks' mindfulness therapy in the treatment of chronic pain in patients with cancer: Pilot study.”,
  2. Rutkowski P. i wsp. 11531 - "The prognostic value of blood neutrophil-to-lymphocyte ratio (NLR) factor in advanced gastrointestinal stromal tumors (GIST) treated with sunitinib after imatinib failure.”,
  3. Długosz-Danecka M. i wsp. e19513 - "Efficacy and safety of obinutuzumab in the frontline treatment of CLL patients with comorbidities: The real-world results of Polish Adult Leukemia Group (PALG) retrospective analysis.”,
  4. Długosz-Danecka M. i wsp. e19542 - "The average relative dose intensity of R-CHOP as an independent prognostic factor determining overall survival in diffuse large B cell lymphoma patients.”,
  5. Jagielska B. i wsp. e12659 - "Survival outcomes for polish women younger than age 40 years receiving trastuzumab for HER2-positive early breast cancer: A National population-based observational study.”,
  6. Jagiełło-Gruszfeld A. i wsp. e12599 - "Are anthracyclines needed for the neoadjuvant treatment of patients with HER2-positive early breast cancer?”,
  7. Kwapisz D.M. e21558 - "Clinical characteristics and outcomes associated with molecular status and treatment with vemurafenib in metastatic melanoma (MM) in a real-world setting: Comparison of four groups.',
  8. Lewandowska M.A. i wsp. e13615 - "Whole BRCA1/2 exome screening in breast cancer tissue: Preliminary study on 45 patients negative in preventive screening analysis in Poland which cover the most common mutations in BRCA1/2 tested in blood.”,
  9. Niwinska A. i wsp. e12561 - "Should radiotherapy be succeed tumorectomy in patients with low risk ductal carcinoma in situ (DCIS) when using Van Nuys Prognostic Index based treatment?”,
  10. Ramlau R. i wsp. e22081- "Expression of kynurenine aminotransferase I as a prognostic factor in the context of the occurrence of neurological symptoms during chemotherapy.”,
  11. Rogowski W. i wsp. e15570 - "Adding oxaliplatin (OX) to neoadjuvant therapy of locally advanced rectal cancer (LARC): Still a promising option?”,
  12. Spałek M. I wsp. e15706 - "Impact of prior pelvic bone marrow irradiation on toxicity of oxaliplatin-based chemotherapy in rectal cancer.”,
  13. Żok J. i wsp. e15671 - "Cumulative dose of oxaliplatin in adjuvant therapy for stage III colon cancer patients: Impact on survival.”.